Hester Biosciences growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+6.9%+2.2%+14.5%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+41.9%+13.8%+6.0%
+53.2%+21.3%+22.0%
+99.4%+36.2%−24.5%
+99.4%+36.2%−24.5%
+3.8%−1.4%−1.1%
+12.6%+7.9%+5.0%
−0.6%+34.0%+104.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

HESTERBIO₹2,307.60

Hester Biosciences Limited

· Pharma & Health
₹ CrorePeersWINDLASSYNCOMFNGLFINEINDOCOSAIPARENTJAGSNPHARMPANACEABIOMcap ₹1,963 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+14.5+2.2+6.9—
EBITDA Growth—+6.0+13.8+41.9—
EBIT Growth—+22.0+21.3+53.2—
Net Income Growth—-24.5+36.2+99.4—
EPS Growth—-24.5+36.2+99.4—
Total Assets Growth—-1.1-1.4+3.8—
Total Equity Growth—+5.0+7.9+12.6—
Cash from Operations Growth—+104.0+34.0-0.6—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.